@entity1556 prior to or during early pregnancy is associated with increased risk for XXXX in pregnancy and gestational diabetes.

@entity1 @entity101 @entity6 @entity3036 @entity1468 @entity13520 @entity1556 @entity413
OBJECTIVE: To examine whether and to what extent pre/early-pregnancy blood pressure (BP) in the prehypertensive range contributes to the development of @entity101 in @entity6 ( @entity6 ). METHODS: The cohort consisted of @entity1 who had their prenatal care and delivered a live singleton neonate at the Kaiser Permanente Bellflower Medical Center during 2005-2010. @entity1 with prepregnancy @entity101 ( @entity101 ) were excluded from the analysis. Among the remaining @entity1 , pre/early-pregnancy @entity1556 ( @entity1556 ) was defined as two consecutive elevated BPs (SBP>= 120 or @entity13520 ) at separate ambulatory visits in the period from 1 year prior to pregnancy through the first trimester. @entity101 disorders of pregnancy, including @entity1468 / @entity3036 (PE/E), were identified by ICD-9 diagnoses. Mid-pregnancy 75-g oral @entity413 tolerance tests were used to identify @entity6 . Multivariable logistic and robust Poisson regression was used to test the association between @entity1556 and each outcome, adjusted for potential confounders. RESULTS: Among 7802 @entity1 with at least two BP measures prior to or early in pregnancy, 2156 (27.6%) had @entity1556 . Overall, 653 (8.4%) developed a @entity101 of pregnancy, 373 (4.8%) had PE/E, and 1877 (24.1%) developed @entity6 . After covariate adjustment, @entity1 with @entity1556 were 2.65 [95% confidence interval (CI) 2.22-3.16], 2.17 (95% CI 1.72-2.73), and 1.20 (95% CI 1.09-1.33) times as likely to develop any @entity101 , PE/E, and @entity6 , respectively, compared to normotensive @entity1 . CONCLUSION: Prospective studies aimed at evaluating whether @entity1 with @entity1556 detected prior to or early in pregnancy may benefit from more intensive screening and/or interventions to prevent @entity101 in pregnancy and @entity6 are needed.
